Clinical Trial Update: Proof-of-concept, Open-label Study in Patients With Early Alzheimer's Disease [Phase 2]

View source ↗

Summary

Phase 2 open-label proof-of-concept study in early Alzheimer's disease has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Snippet

Sponsor: NewAmsterdam Pharma | Conditions: Early Alzheimer's Disease | Phase 2 | Status: COMPLETED | Results posted: 2024-11-19